+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID06902545

Observational Study of VYLOY Zolbetuximab Safety in Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in South Korea

Led by Astellas Pharma Korea, Inc. · Updated on 2026-10-22

377

Participants Needed

15

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are observing the safety of VYLOY zolbetuximab in people in South Korea who have locally advanced, unresectable, or metastatic gastric cancer or gastroesophageal junction GEJ cancer. These cancers involve tumors in or near the stomach or where the esophagus meets the stomach. The study aims to collect real-world information on how safe VYLOY is and also to learn how long the cancer remains stable under treatment. This is an observational study lasting about one year. Participants will receive VYLOY as part of their usual care following the approved local treatment guidelines. VYLOY is given by slow injection into a vein. The study does not assign treatments but observes patients who are receiving VYLOY 100 mg or 300 mg doses as per clinical practice. This approach allows researchers to gather safety data in typical clinical settings. During the approximately 54-week study period following the first VYLOY dose, researchers will monitor participants for adverse events and adverse drug reactions, including serious and unexpected ones. They will also track deaths and important risks compared to evaluations. Additionally, the study will measure how long patients live without their cancer getting worse. The participants doctors manage their treatment, and the study collects information without changing their care.

CONDITIONS

Brief Title

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Research Team

A

Astellas Pharma Global Development, Inc.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here